ID   B3GT6_HUMAN             Reviewed;         329 AA.
AC   Q96L58; Q5T7M5;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   10-MAY-2017, entry version 132.
DE   RecName: Full=Beta-1,3-galactosyltransferase 6;
DE            Short=Beta-1,3-GalTase 6;
DE            Short=Beta3Gal-T6;
DE            Short=Beta3GalT6;
DE            EC=2.4.1.134;
DE   AltName: Full=GAG GalTII;
DE   AltName: Full=Galactosyltransferase II;
DE   AltName: Full=Galactosylxylosylprotein 3-beta-galactosyltransferase;
DE   AltName: Full=UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6;
GN   Name=B3GALT6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=11551958; DOI=10.1074/jbc.M107339200;
RA   Bai X., Zhou D., Brown J.R., Crawford B.E., Hennet T., Esko J.D.;
RT   "Biosynthesis of the linkage region of glycosaminoglycans: cloning and
RT   activity of galactosyltransferase II, the sixth member of the beta
RT   1,3-galactosyltransferase family (beta 3GalT6).";
RL   J. Biol. Chem. 276:48189-48195(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   COFACTOR.
RX   PubMed=9892646; DOI=10.1073/pnas.96.2.406;
RA   Zhou D., Dinter A., Gutierrez Gallego R., Kamerling J.P.,
RA   Vliegenthart J.F.G., Berger E.G., Hennet T.;
RT   "A beta-1,3-N-acetylglucosaminyltransferase with poly-N-
RT   acetyllactosamine synthase activity is structurally related to beta-
RT   1,3-galactosyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:406-411(1999).
RN   [4]
RP   ERRATUM.
RA   Zhou D., Dinter A., Gutierrez Gallego R., Kamerling J.P.,
RA   Vliegenthart J.F.G., Berger E.G., Hennet T.;
RL   Proc. Natl. Acad. Sci. U.S.A. 97:11673-11673(2000).
RN   [5]
RP   VARIANTS SEMDJL1 GLY-65; LEU-67; ASN-156; CYS-232 AND SER-300,
RP   VARIANTS EDSP2 TRP-6; 139-MET--ALA-141 DEL AND THR-309, AND
RP   CHARACTERIZATION OF VARIANTS SEMDJL1 GLY-65; LEU-67; ASN-156; CYS-232
RP   AND SER-300.
RX   PubMed=23664117; DOI=10.1016/j.ajhg.2013.04.003;
RA   Nakajima M., Mizumoto S., Miyake N., Kogawa R., Iida A., Ito H.,
RA   Kitoh H., Hirayama A., Mitsubuchi H., Miyazaki O., Kosaki R.,
RA   Horikawa R., Lai A., Mendoza-Londono R., Dupuis L., Chitayat D.,
RA   Howard A., Leal G.F., Cavalcanti D., Tsurusaki Y., Saitsu H.,
RA   Watanabe S., Lausch E., Unger S., Bonafe L., Ohashi H.,
RA   Superti-Furga A., Matsumoto N., Sugahara K., Nishimura G., Ikegawa S.;
RT   "Mutations in B3GALT6, which encodes a glycosaminoglycan linker region
RT   enzyme, cause a spectrum of skeletal and connective tissue
RT   disorders.";
RL   Am. J. Hum. Genet. 92:927-934(2013).
RN   [6]
RP   VARIANTS SEMDJL1 HIS-207 AND SER-217.
RX   PubMed=23664118; DOI=10.1016/j.ajhg.2013.04.016;
RA   Malfait F., Kariminejad A., Van Damme T., Gauche C., Syx D.,
RA   Merhi-Soussi F., Gulberti S., Symoens S., Vanhauwaert S., Willaert A.,
RA   Bozorgmehr B., Kariminejad M.H., Ebrahimiadib N., Hausser I.,
RA   Huysseune A., Fournel-Gigleux S., De Paepe A.;
RT   "Defective Initiation of Glycosaminoglycan Synthesis due to B3GALT6
RT   Mutations causes a pleiotropic Ehlers-Danlos syndrome-like connective
RT   tissue disorder.";
RL   Am. J. Hum. Genet. 92:935-945(2013).
CC   -!- FUNCTION: Beta-1,3-galactosyltransferase that transfers galactose
CC       from UDP-galactose to substrates with a terminal beta-linked
CC       galactose residue. Has a preference for galactose-beta-1,4-xylose
CC       that is found in the linker region of glycosaminoglycans, such as
CC       heparan sulfate and chondroitin sulfate. Has no activity towards
CC       substrates with terminal glucosamine or galactosamine residues.
CC       {ECO:0000269|PubMed:11551958}.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-galactose + 4-beta-D-galactosyl-O-
CC       beta-D-xylosyl-[protein] = UDP + 3-beta-D-galactosyl-4-beta-D-
CC       galactosyl-O-beta-D-xylosyl-[protein].
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:9892646};
CC   -!- PATHWAY: Glycan metabolism; chondroitin sulfate biosynthesis.
CC   -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane
CC       {ECO:0000269|PubMed:11551958}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:11551958}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:11551958}.
CC   -!- DISEASE: Ehlers-Danlos syndrome, progeroid type, 2 (EDSP2)
CC       [MIM:615349]: A variant form of Ehlers-Danlos syndrome
CC       characterized by an aged appearance, developmental delay, short
CC       stature, craniofacial disproportion, generalized osteopenia,
CC       defective wound healing, hypermobile joints, hypotonic muscles,
CC       and loose but elastic skin. {ECO:0000269|PubMed:23664117}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Spondyloepimetaphyseal dysplasia with joint laxity, 1,
CC       with or without fractures (SEMDJL1) [MIM:271640]: A bone disease
CC       characterized by vertebral abnormalities and ligamentous laxity
CC       that result in spinal misalignment and progressive severe
CC       kyphoscoliosis, thoracic asymmetry, and respiratory compromise
CC       resulting in early death. Additional skeletal features include
CC       elbow deformities with radial head dislocation, dislocated hips,
CC       clubfeet, and tapered fingers with spatulate distal phalanges.
CC       Many affected children have an oval face, flat midface, prominent
CC       eyes with blue sclerae, and a long philtrum. Palatal abnormalities
CC       and congenital heart disease are also observed.
CC       {ECO:0000269|PubMed:23664117, ECO:0000269|PubMed:23664118}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 31 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: PubMed:9892646 describes the wrong protein; the cDNAs
CC       used had been switched inadvertently. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase;
CC       Note=Beta-1,3-galactosyltransferase 6;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_433";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY050570; AAL11442.1; -; mRNA.
DR   EMBL; AL162741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS13.1; -.
DR   RefSeq; NP_542172.2; NM_080605.3.
DR   UniGene; Hs.284284; -.
DR   ProteinModelPortal; Q96L58; -.
DR   BioGrid; 126016; 5.
DR   STRING; 9606.ENSP00000368496; -.
DR   CAZy; GT31; Glycosyltransferase Family 31.
DR   iPTMnet; Q96L58; -.
DR   PhosphoSitePlus; Q96L58; -.
DR   BioMuta; B3GALT6; -.
DR   DMDM; 61211870; -.
DR   EPD; Q96L58; -.
DR   MaxQB; Q96L58; -.
DR   PaxDb; Q96L58; -.
DR   PeptideAtlas; Q96L58; -.
DR   PRIDE; Q96L58; -.
DR   DNASU; 126792; -.
DR   Ensembl; ENST00000379198; ENSP00000368496; ENSG00000176022.
DR   GeneID; 126792; -.
DR   KEGG; hsa:126792; -.
DR   UCSC; uc001adk.4; human.
DR   CTD; 126792; -.
DR   DisGeNET; 126792; -.
DR   GeneCards; B3GALT6; -.
DR   H-InvDB; HIX0028666; -.
DR   HGNC; HGNC:17978; B3GALT6.
DR   MalaCards; B3GALT6; -.
DR   MIM; 271640; phenotype.
DR   MIM; 615291; gene.
DR   MIM; 615349; phenotype.
DR   neXtProt; NX_Q96L58; -.
DR   OpenTargets; ENSG00000176022; -.
DR   Orphanet; 75496; Ehlers-Danlos syndrome, progeroid type.
DR   Orphanet; 93359; Spondyloepimetaphyseal dysplasia with joint laxity.
DR   PharmGKB; PA25214; -.
DR   eggNOG; KOG2288; Eukaryota.
DR   eggNOG; ENOG410XV5H; LUCA.
DR   GeneTree; ENSGT00530000063810; -.
DR   HOGENOM; HOG000230579; -.
DR   HOVERGEN; HBG050652; -.
DR   InParanoid; Q96L58; -.
DR   KO; K00734; -.
DR   OMA; HRTLTHE; -.
DR   OrthoDB; EOG091G0G46; -.
DR   PhylomeDB; Q96L58; -.
DR   TreeFam; TF314311; -.
DR   BioCyc; MetaCyc:HS10991-MONOMER; -.
DR   BRENDA; 2.4.1.134; 2681.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   UniPathway; UPA00755; -.
DR   UniPathway; UPA00756; -.
DR   ChiTaRS; B3GALT6; human.
DR   GenomeRNAi; 126792; -.
DR   PRO; PR:Q96L58; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000176022; -.
DR   CleanEx; HS_B3GALT6; -.
DR   Genevisible; Q96L58; HS.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005797; C:Golgi medial cisterna; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0047220; F:galactosylxylosylprotein 3-beta-galactosyltransferase activity; TAS:Reactome.
DR   GO; GO:0008499; F:UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity; IEA:Ensembl.
DR   GO; GO:0035250; F:UDP-galactosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0030206; P:chondroitin sulfate biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006486; P:protein glycosylation; IEA:InterPro.
DR   InterPro; IPR002659; Glyco_trans_31.
DR   PANTHER; PTHR11214; PTHR11214; 1.
DR   Pfam; PF01762; Galactosyl_T; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disease mutation; Dwarfism; Ehlers-Danlos syndrome;
KW   Glycoprotein; Glycosyltransferase; Golgi apparatus; Manganese;
KW   Membrane; Polymorphism; Reference proteome; Signal-anchor;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    329       Beta-1,3-galactosyltransferase 6.
FT                                /FTId=PRO_0000219168.
FT   TOPO_DOM      1     11       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     12     34       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     35    329       Lumenal. {ECO:0000255}.
FT   COMPBIAS     47     52       Poly-Pro.
FT   CARBOHYD    131    131       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT       6      6       R -> W (in EDSP2; dbSNP:rs397514722).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070132.
FT   VARIANT      65     65       S -> G (in SEMDJL1; the activity of the
FT                                enzyme is significantly decreased;
FT                                dbSNP:rs397514719).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070133.
FT   VARIANT      67     67       P -> L (in SEMDJL1; loss of activity;
FT                                dbSNP:rs397514720).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070134.
FT   VARIANT     139    141       Missing (in EDSP2).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070135.
FT   VARIANT     156    156       D -> N (in SEMDJL1; loss of activity;
FT                                dbSNP:rs397514718).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070136.
FT   VARIANT     174    174       E -> D (in dbSNP:rs12085009).
FT                                /FTId=VAR_059317.
FT   VARIANT     207    207       D -> H (in SEMDJL1; dbSNP:rs397514723).
FT                                {ECO:0000269|PubMed:23664118}.
FT                                /FTId=VAR_070137.
FT   VARIANT     217    217       G -> S (in SEMDJL1; dbSNP:rs397514724).
FT                                {ECO:0000269|PubMed:23664118}.
FT                                /FTId=VAR_070138.
FT   VARIANT     232    232       R -> C (in SEMDJL1; the activity of the
FT                                enzyme is significantly decreased;
FT                                dbSNP:rs397514717).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070139.
FT   VARIANT     300    300       C -> S (in SEMDJL1; loss of activity;
FT                                dbSNP:rs786200939).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070140.
FT   VARIANT     309    309       S -> T (in EDSP2; dbSNP:rs397514721).
FT                                {ECO:0000269|PubMed:23664117}.
FT                                /FTId=VAR_070141.
FT   CONFLICT      2      2       K -> N (in Ref. 1; AAL11442).
FT                                {ECO:0000305}.
SQ   SEQUENCE   329 AA;  37138 MW;  F4E2A219B1DC11F7 CRC64;
     MKLLRRAWRR RAALGLGTLA LCGAALLYLA RCAAEPGDPR AMSGRSPPPP APARAAAFLA
     VLVASAPRAA ERRSVIRSTW LARRGAPGDV WARFAVGTAG LGAEERRALE REQARHGDLL
     LLPALRDAYE NLTAKVLAML AWLDEHVAFE FVLKADDDSF ARLDALLAEL RAREPARRRR
     LYWGFFSGRG RVKPGGRWRE AAWQLCDYYL PYALGGGYVL SADLVHYLRL SRDYLRAWHS
     EDVSLGAWLA PVDVQREHDP RFDTEYRSRG CSNQYLVTHK QSLEDMLEKH ATLAREGRLC
     KREVQLRLSY VYDWSAPPSQ CCQRREGIP
//
